Viridian Therapeutics enters its May 7 earnings call riding one of the sharpest weekly moves in the biotech universe — up 38% in five sessions to $18.75, with a single-day gain of 33% on May 5 doing almost all the work.
The story here is a clinical catalyst colliding with a meaningful short base. Short interest has climbed 26% over the past month to 11% of the free float — roughly 10.5 million shares — making this a genuinely crowded short heading into a binary event. That short build accelerated through mid-April, when SI briefly touched its recent peak near 10.8 million shares, before trimming only modestly in the days that followed. The stock's 33% one-day explosion almost certainly forced a wave of painful covering, yet the ORTEX daily estimate shows short interest barely moved on May 5 — up a fractional 0.8% on the day — suggesting shorts largely held their ground rather than fled. That's a notable read: with earnings less than 24 hours away, the bears are not blinking.
Borrow conditions tell a different story than the short-size numbers might suggest. Despite 11% short interest, availability is remarkably loose at over 2,100% of estimated short interest — meaning there are more than twenty shares available to borrow for every one already lent out. Cost to borrow has edged up 11% over the week but remains trivially low at 0.51% annualised. The ORTEX short score is a moderate 51.3, and availability has been consistently ample throughout April. There is no squeeze pressure here; bears can add without fighting for stock. The options market had been deeply defensive heading into this week — the put/call ratio was running at 4.1 in early April, close to its 52-week peak — but has unwound sharply to 2.04 now, roughly 0.7 standard deviations below its 20-day average. That suggests the heavy put protection that built up during the selloff has partially been monetised, or rolled out, into this week's rally.
The Street's posture is uniformly bullish on direction, more nuanced on price. Every analyst covering VRDN currently carries a Buy or Outperform rating — Goldman Sachs, RBC Capital, Needham, Truist, Wedbush, and Evercore ISI are all in the bull camp. The consensus mean target is $34.13, implying roughly 82% upside from current levels, though that figure partly reflects targets set before the stock's mid-April collapse. RBC's Lisa Walter raised her target to $34 from $30 just yesterday — the first upward revision in weeks — while Needham reiterated its $32 Buy the day prior. Earlier in April, Goldman, RBC, Truist, Wedbush, and Evercore all trimmed targets by varying degrees, with some cuts approaching 30%, as the REVEAL-1 study data disappointed on proptosis response rates relative to expectations. The bull case rests on veligrotug remaining approvable and a potential subcutaneous label expansion via elegrobart. Bears point to a slowing proptosis response rate, a higher-than-expected placebo effect, and competition from established thyroid eye disease players.
Institutional ownership shows a concentrated shareholder base that has been actively adding. FMR (Fidelity) added over 2.1 million shares in the most recent reporting period to reach a 14% position. BlackRock added 1 million shares, Vanguard added 1.3 million, and State Street and T. Rowe Price each added over 1 million. Fairmount Funds Management — a biotech-specialist fund that also sits on the board and owns nearly 4% — bought 454,545 shares at $22 in October 2025 in an open-market purchase, a meaningful vote of confidence at levels above where the stock traded for much of April.
Prior earnings reactions have been contained — a 2.6% gain the day after the February 2026 print, a 1.5% bounce in late February's separate release, and a modest 0.6% dip after the November 2025 result — though the five-day windows have been more volatile, with the February print ultimately resolving 3.9% lower over the following week. The setup heading into May 7 is fundamentally different from those events: the stock has just posted an extraordinary single-day move, short interest remains elevated, and the options market has come in considerably from its peak defensiveness. The key question the print must answer is whether the REVEAL-1 proptosis data is sufficient for an approvable label, and whether management can articulate a differentiated commercial path alongside elegrobart's subcutaneous programme — everything else is secondary.
See the live data behind this article on ORTEX.
Open VRDN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
